’Big Short’ Michael Burry de-registers Scion Asset Management
AstraZeneca PLC ADR has reached a significant milestone as its stock hit a 52-week high of 86.57 USD, with the current price hovering at 86.51 USD. This achievement highlights the company’s robust performance over the past year, with the stock delivering an impressive 33.9% total return over the last 12 months and an even stronger 26.03% gain in just the past six months. The pharmaceutical giant’s recent advancements and strategic initiatives have likely contributed to this upward trajectory, reflecting investor confidence and market optimism. With a market capitalization of nearly $268 billion and an overall "GREAT" financial health rating from InvestingPro, AstraZeneca stands as a prominent player in the pharmaceuticals industry. The company has also maintained dividend payments for 33 consecutive years, demonstrating long-term stability. InvestingPro analysis suggests the stock is currently undervalued, with additional ProTips available to subscribers through their comprehensive Pro Research Report, one of 1,400+ detailed analyses that transform complex Wall Street data into actionable intelligence.
In other recent news, AstraZeneca reported third-quarter product sales of $14.365 billion, surpassing consensus estimates of $14.031 billion. The oncology segment played a significant role in this revenue beat, with strong performances from several key products. Leerink Partners responded by raising AstraZeneca’s stock price target to $87 from $85, maintaining an Outperform rating. Additionally, Jefferies upgraded AstraZeneca’s stock rating from Hold to Buy, citing the undervaluation of its oncology portfolio.
The European Commission has approved AstraZeneca’s Koselugo for treating symptomatic, inoperable plexiform neurofibromas in adults with neurofibromatosis type 1. This approval is based on positive results from the KOMET Phase III trial. AstraZeneca’s FASENRA also showed promising results in a Phase III trial for hypereosinophilic syndrome, reducing the risk of disease worsening by 65%. In corporate developments, AstraZeneca’s non-executive director Euan Ashley has joined the board of DexCom, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.